Hormones and fatty liver study
Part of Digestive system clinical trials.
This study looks at how hormones (androgens) relate to fatty liver disease (MASH) in women, especially those with PCOS. It aims to understand why some women develop worse liver problems and might help find new ways to treat or prevent them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either MASH (fatty liver with inflammation) or PCOS (polycystic ovary syndrome), or you don't have PCOS.
- You drink no more than 7 alcoholic drinks per week.
- You are not currently pregnant.
- Your fatty liver isn't caused by something else (like certain medications or a genetic condition).
- You haven't lost more than 10% of your body weight in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called bicalutamide (an anti-androgen) to see if it can help young women with both PCOS and fatty liver disease (NASH). The goal is to find a new treatment option for these two conditions together.
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
This study looks at people with fatty liver disease and common health issues like obesity, diabetes, high blood pressure, or abnormal cholesterol. It may help researchers understand how liver fat and heart/metabolism problems relate and how they affect health over time.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
This trial tests a new experimental drug called OPK-88006 to see if it can help treat MASH, a serious liver condition linked to excess fat buildup. The study has two parts: one with healthy volunteers to check safety, and one with people who have signs of fatty liver disease.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.